ADAP Advocacy and the Partnership for Safe Medicines (PSM) issued a joint statement warning pharmacists that all discounted HIV products bought from online pharmacy-to-pharmacy (P2P) marketplaces fit the definition of suspect product under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act. Pharmacies should not buy from these platforms, and any HIV medicines purchased from them should be considered suspect, requiring quarantine and verification before dispensing. Patients living with HIV/AIDS are potentially being put at risk.
PSM's Executive Director, Shabbir Imber Safdar, warned: "A deeply discounted HIV product bought off the internet from an unknown seller who won't provide a pedigree qualifies as suspect even before the purchasing pharmacy receives it because the listing alone meets many of the U.S. Food and Drug Administration's risk criteria for illegitimacy: deep discounts, an established pattern of fraud in the HIV drug supply chain over the last six years, unknown sellers, and incomplete transaction histories. Once received, the often-observed damage to the packaging confirms that this product will need to be quarantined and investigated."
Online P2P marketplaces help pharmacies manage inventory but pose risks of suspicious sales. Dispensers must quarantine and investigate suspect products and report illegitimate products to the FDA and partners within 24 hours. The full warning is available at https://www.safemedicines.org/diverted-hiv-meds-on-p2p-platforms.
Brandon M. Macsata, CEO of ADAP Advocacy, added: "Independent pharmacies have also been known to trade stock in less formal settings such as WhatsApp or Telegram. Those transactions are, if anything, more vulnerable and never advisable. We're strongly urging pharmacists to heed our warning and avoid exposing patients to unnecessary risks."
The implication of this announcement is significant for patient safety and pharmacy compliance. The diversion of HIV medicines through P2P platforms undermines the integrity of the drug supply chain and poses serious health risks to patients who may receive counterfeit, substandard, or improperly stored medications. Pharmacists are now on notice that purchasing from these platforms not only violates FDA guidelines but also endangers lives. This warning underscores the need for rigorous supply chain oversight and the importance of sourcing medications from legitimate, traceable channels. For patients, it highlights the potential dangers of relying on pharmacies that may unknowingly dispense suspect products, emphasizing the critical role of regulatory compliance in protecting public health.
